Clinical Trial Update: A Phase III Confirmatory Study of K-877 Extended Release Tablet [Phase 3]

View source ↗

Summary

A Phase III confirmatory study of K-877 Extended Release Tablet (pemafibrate) for dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• K-877 Extended Release Tablet (pemafibrate)

Snippet

Sponsor: Kowa Company, Ltd. | Conditions: Dyslipidemias | Phase 3 | Status: COMPLETED